206 related articles for article (PubMed ID: 26047622)
21. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
22. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Sutani A; Nagai Y; Udagawa K; Uchida Y; Koyama N; Murayama Y; Tanaka T; Miyazawa H; Nagata M; Kanazawa M; Hagiwara K; Kobayashi K
Br J Cancer; 2006 Dec; 95(11):1483-9. PubMed ID: 17106442
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
[TBL] [Abstract][Full Text] [Related]
25. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC
Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137
[TBL] [Abstract][Full Text] [Related]
26. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
27. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
[TBL] [Abstract][Full Text] [Related]
28. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
29. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
31. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
[TBL] [Abstract][Full Text] [Related]
32. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Dziadziuszko R; Witta SE; Cappuzzo F; Park S; Tanaka K; Danenberg PV; Barón AE; Crino L; Franklin WA; Bunn PA; Varella-Garcia M; Danenberg KD; Hirsch FR
Clin Cancer Res; 2006 May; 12(10):3078-84. PubMed ID: 16707605
[TBL] [Abstract][Full Text] [Related]
34. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
[TBL] [Abstract][Full Text] [Related]
35. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.
Asano H; Toyooka S; Tokumo M; Ichimura K; Aoe K; Ito S; Tsukuda K; Ouchida M; Aoe M; Katayama H; Hiraki A; Sugi K; Kiura K; Date H; Shimizu N
Clin Cancer Res; 2006 Jan; 12(1):43-8. PubMed ID: 16397022
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
[TBL] [Abstract][Full Text] [Related]
37. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
Soh J; Okumura N; Lockwood WW; Yamamoto H; Shigematsu H; Zhang W; Chari R; Shames DS; Tang X; MacAulay C; Varella-Garcia M; Vooder T; Wistuba II; Lam S; Brekken R; Toyooka S; Minna JD; Lam WL; Gazdar AF
PLoS One; 2009 Oct; 4(10):e7464. PubMed ID: 19826477
[TBL] [Abstract][Full Text] [Related]
38. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
Marchetti A; Del Grammastro M; Filice G; Felicioni L; Rossi G; Graziano P; Sartori G; Leone A; Malatesta S; Iacono M; Guetti L; Viola P; Mucilli F; Cuccurullo F; Buttitta F
PLoS One; 2012; 7(7):e42164. PubMed ID: 22848739
[TBL] [Abstract][Full Text] [Related]
39. Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.
Evans M; Summers Y; Taylor P; Harris M; Bayman N; Faivre-Finn C; Sheikh H; Burt P; Blackhall F; Califano R
Lung Cancer; 2013 Dec; 82(3):510-1. PubMed ID: 24138902
[No Abstract] [Full Text] [Related]
40. Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.
Yu CC; Qiu W; Juang CS; Mansukhani MM; Halmos B; Su GH
Cancer Lett; 2017 Jan; 384():86-93. PubMed ID: 27725226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
